In a recent OncLive Peer Exchange, Dr. Gregory Vidal partnered with a panel of breast oncology experts to discuss the standard-of-care treatment approaches for early-stage HR-positive/HER2-negative breast cancer. Topics include: – Evolution of HER2-negative management – Updates in HR-positive treatment – Importance of genetic testing – Utilization of endocrine therapy – BRCA mutations and… Read more »